The case for tumour-agnostic reimbursement of dual immunotherapy
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116784 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Vivek Subbiah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: viveksubbiah@outlook.com. Hauptthemen laut MEDLINE: Neoplasms, Ipilimumab, Immunotherapy, Nivolumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Barjesteh van Waalwijk van Doorn-Khosrovani and colleagues raise important questions about this recommendation for tumour-agnostic reimbursement of nivolumab and ipilimumab in Australia. We respectfully offer a counterpoint and endorse the broad coverage. In 2025, Pharmaceutical Benefits Advisory Committee (PBAC) proposed that prescribing nivolumab and ipilimumab be guided by clinical judgement informed by the best available evidence for undefined "immunotherapy-sensitive" advanced or metastatic cancers, and, in January 2026 made a similar recommendation for pembrolizumab. Patients with rare and ultra-rare cancers, including but not limited to angiosarcoma, alveolar soft part sarcoma, gestational trophoblastic disease, small cell carcinoma of the ovary (hypercalcemic type), and adrenocortical carcinoma, face profound unmet need. Within many of these diseases, a subset of patients derives substantial benefit from immunotherapy. For example, the SWOG DART (Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors) trial, the largest prospective evaluation of nivolumab plus ipilimumab in rare/ultra-rare cancers, demonstrated clinically meaningful activity across multiple histologies, without biomarker selection. Notably, some patients with metastatic disease remain disease-free years after treatment, outcomes rarely achieved with chemotherapy or supportive care in refractory settings. Therefore, concerns that biomarker-agnostic approval signals an evidentiary retreat overlook both our incomplete understanding immune sensitivity and the global access limits to comprehensive genomic testing. Importantly, clinical judgement is not arbitrary; it reflects training, experience, ethical reasoning, and patient-centred decision making. The question is whether demanding perfect evidence should prevent access to potentially transformative treatment. Grounded in evidence and expertise, PBAC's decision prioritises meaningful access to effective therapy for patients with few alternatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: viveksubbiah@outlook.com.
- Center for Precision Oncology and Rare Cancers at Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA; WIN Consortium, Paris, France.
Zitieren
APA
Subbiah, V., & Kurzrock, R. (2026). The case for tumour-agnostic reimbursement of dual immunotherapy. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116784
Vancouver
Subbiah V, Kurzrock R. The case for tumour-agnostic reimbursement of dual immunotherapy. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116784
BibTeX
@article{Subbiah2026,
author = {Subbiah, Vivek and Kurzrock, Razelle},
title = {The case for tumour-agnostic reimbursement of dual immunotherapy},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116784}
}
EUVIMED